Business Context and Reporting Period
This Form 8-K Current Report was filed by Altimmune, Inc. on May 11, 2020. The filing reports a corporate governance event: the appointment of a new director to the Board of Directors, effective May 11, 2020.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or operational metrics.
Material Changes
The material change reported is the addition of Diane Jorkasky, M.D., to the Board of Directors. Dr. Jorkasky brings extensive experience in the biopharmaceutical industry, including prior roles as Executive Vice President and Chief Medical Officer at Complexa Inc. and board service at Alzheon, Inc. and Q Therapeutics, Inc.
Compensation and Arrangements
- Equity: Dr. Jorkasky received an initial option award to purchase 40,000 shares of the Company's common stock under the 2017 Omnibus Incentive Plan.
- Cash Retainer: She is entitled to an annual cash retainer of $40,000 as a non-employee director.
- Indemnification: The Company entered into a standard indemnification agreement with Dr. Jorkasky.
Investor Verification Checklist
- Verify the terms of the 2017 Omnibus Incentive Plan regarding the 40,000 share option grant.
- Review the Company's Non-Employee Director Compensation Policy for details on the $40,000 annual retainer.
- Confirm the absence of any undisclosed material interests or arrangements involving Dr. Jorkasky as stated in the filing.